ALUR on OTC
ALLURION TECHNOLOGIES, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with BIOTRICITY INC., Profound Medical Corp. or Vivos Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
All Other Countries brought in 74% of the revenue ALLURION TECHNOLOGIES, INC. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| All Other Countries | $25.4M | $11.2M |
| Spain | $4.0M | $2.2M |
| Italy | $2.7M | $1.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue37¢$5.7M
- Research and development50¢$7.6M
- Other costs13¢$1.9M
- Income tax0¢$74.0K
Out of $15.2M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $15.2M | $32.1M |
| Cost of revenue | $5.7M | $10.6M |
| Gross profit | $9.6M | $21.5M |
| Sales and marketing | $10.8M | $25.9M |
| Research and development | $7.6M | $17.4M |
| General and administrative | $21.4M | $28.4M |
| Total operating expenses: | $39.7M | $71.7M |
| Loss from operations | -$30.2M | -$50.2M |
| Interest expense | $0 | -$2.3M |
| Changes in fair value of warrants | $12.8M | $17.0M |
| Changes in fair value of debt | -$3.6M | $18.1M |
| Changes in fair value of Revenue Interest Financing and PIPE Conversion Option | -$9.1M | -$4.8M |
| Change in fair value of earn-out liabilities | $1.1M | $22.9M |
| Loss on extinguishment of debt | -$660.0K | -$8.7M |
| Other income (expense), net | $982.0K | $1.5M |
| Total other income: | $1.5M | $43.7M |
| Loss before income taxes | -$28.7M | -$6.5M |
| Provision for income taxes | -$74.0K | -$718.0K |
| Net loss | -$28.8M | -$7.2M |
| Net loss per share - Basic | -$3.81 | -$3.20 |
| Net loss per share - Diluted | -$3.81 | -$3.20 |
| Weighted-average shares outstanding - Basic | 7.5M shares | 2.2M shares |
| Weighted-average shares outstanding - Diluted | 7.5M shares | 2.2M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $5.4M | $15.4M | |
| Accounts receivable, net of allowance of doubtful accounts of $5,159 and $6,701 respectively | $4.0M | $7.1M | |
| Inventory, net | $2.7M | $3.4M | |
| Prepaid expenses and other current assets | $759.0K | $1.2M | |
| Total current assets | $12.8M | $27.2M | |
| Property and equipment, net | $1.4M | $2.5M | |
| Right-of-use asset | $950.0K | $2.1M | |
| Other long-term assets | $663.0K | $1.1M | |
| Total assets | $15.8M | $32.8M | |
| Accounts payable | $3.6M | $6.6M | |
| Current portion of lease liabilities | $398.0K | $869.0K | |
| Accrued expenses and other current liabilities | $6.4M | $11.4M | |
| Current portion of convertible notes payable | $28.1M | $0 | |
| Total current liabilities | $38.4M | $18.9M | |
| Warrant liabilities | $5.8M | $4.6M | |
| Revenue Interest Financing liability | $47.7M | $49.2M | |
| Earn-out liabilities | $31.0K | $1.1M | |
| Convertible notes payable | $0 | $35.7M | |
| Lease liabilities, net of current portion | $571.0K | $1.3M | |
| Other liabilities | $385.0K | $17.0K | |
| Total liabilities | $93.0M | $110.8M | |
| Common stock, $0.0001 par value - 1,000,000,000 shares authorized as of December 31, 2025; 12,279,181 and 2,710,607 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $6.0K | $3.0K | |
| Additional paid-in capital | $168.6M | $152.6M | |
| Accumulated other comprehensive gain (loss) | $5.1M | -$8.4M | |
| Accumulated deficit | -$251.0M | -$222.2M | |
| Total stockholders' deficit | -$77.2M | -$78.0M | -$71.3M |
| Total liabilities and stockholders' deficit | $15.8M | $32.8M | |
| Allowance of doubtful accounts | $5.2M | $6.7M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.0B shares | 1.0B shares | |
| Common stock, shares issued | 12.3M shares | 2.7M shares | |
| Common stock, shares outstanding | 12.3M shares | 2.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$28.8M | -$7.2M |
| Non-cash lease expense | $679.0K | $765.0K |
| Depreciation and amortization | $983.0K | $997.0K |
| Stock-based compensation | $3.1M | $3.1M |
| Provision for uncollectible accounts | $2.8M | $1.4M |
| Unrealized exchange gain (loss) and other | -$206.0K | $594.0K |
| Provision for inventory | $1.2M | $2.2M |
| Change in fair value of warrant liabilities | -$12.8M | -$17.0M |
| Change in fair value of derivative liabilities | -$1.9M | |
| Change in fair value of debt | $3.6M | -$18.1M |
| Change in fair value of Revenue Interest Financing and PIPE Conversion Option | $9.1M | $4.8M |
| Change in fair value of earn-out liabilities | -$1.1M | -$22.9M |
| Change in fair value of RTW Share Obligation | $370.0K | |
| Interest paid on debt recorded at fair value | -$2.4M | -$3.1M |
| Non-cash interest expense | $1.5M | |
| Loss on extinguishment of debt | $660.0K | $8.7M |
| Debt issuance costs associated with debt recorded at fair value | $1.4M | |
| Issuance costs associated with warrants recorded at fair value | $1.5M | $942.0K |
| Accounts receivable | $844.0K | $9.0M |
| Inventory | -$486.0K | $543.0K |
| Prepaid expenses, other current and long-term assets | $800.0K | $913.0K |
| Lease liabilities | -$796.0K | -$836.0K |
| Accounts payable | -$3.1M | -$3.9M |
| Accrued expenses and other current liabilities | -$5.0M | -$4.1M |
| Net cash used in operating activities | -$28.9M | -$42.3M |
| Purchases of property and equipment | -$611.0K | |
| Net cash used in investing activities | -$611.0K | |
| Proceeds from issue of convertible notes | $48.0M | |
| Proceeds from private offerings, net of issuance costs | $4.6M | $2.6M |
| Proceeds from public offerings, net of issuance costs | $13.6M | $17.7M |
| Payment of debt issuance costs | -$1.4M | |
| Repayment of Fortress Term Loan | -$47.7M | |
| Proceeds from option and warrant exercises | $26.0K | |
| Proceeds from equity line financing | $795.0K | $1.0M |
| Net cash provided by financing activities | $19.0M | $20.2M |
| Net decrease in cash and cash equivalents and restricted cash | -$10.0M | -$22.7M |
| Cash paid for interest | $2.7M | |
| Deferred financing costs in accounts payable and accrued expenses | $115.0K | $323.0K |
| Change in fair value of RTW Convertible Notes through OCI | $5.3M | -$4.7M |
| Change in fair value of Revenue Interest Financing through OCI | $8.2M | -$4.4M |
| Conversion of Series A Preferred Stock into Common Stock | -$979.0K | |
| Common stock issued for conversion of convertible notes | -$6.6M | |
| Exercise of PIPE Conversion Option | -$547.0K |
Former names
- ALLURION TECHNOLOGIES HOLDINGS, INC.Feb 9, 2023 to Aug 1, 20232
Recent filings
- Oct 13, 202625-NSE
- Sep 2, 2026SCHEDULE 13D/A
- Aug 24, 20268-K
- Aug 14, 2026NT 10-Q
- Jul 24, 20268-K
- Jul 23, 20268-K
- Jul 23, 20264
- Jul 23, 2026SCHEDULE 13D/A
- Jul 7, 20268-K
- Jun 30, 20268-K
- Jun 17, 20268-K
- May 27, 20268-K
- May 15, 202610-Q
- Mar 30, 202610-K
- Mar 12, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8